Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | PRNP | P04156 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351059 | 0.86 | PIK3CA (0.39) | PIK3CAPIK3R1ALDH1A1LMNAHTT | |
| SCHEMBL20350896 | 0.81 | NQO2 (0.46) | PIK3CAPIK3R1ALDH1A1HDAC1PRNP | |
| SCHEMBL28452632 | 0.79 | SCN4A (0.34) | PIK3CALMNAHDAC1TSHR | |
| SCHEMBL20351141 | 0.77 | PIK3CA (0.40) | PIK3CAALDH1A1HRH4HDAC1PRNP | |
| SCHEMBL28454444 | 0.77 | PIK3CA (0.36) | PIK3CAPIK3R1HDAC1 | |
| SCHEMBL28449889 | 0.76 | PIK3CA (0.39) | PIK3CAPIK3R1HDAC1 | |
| SCHEMBL28457784 | 0.76 | PIK3CA (0.38) | PIK3CAPIK3R1HDAC1 | |
| SCHEMBL28454600 | 0.76 | HTR1B (0.41) | PIK3CAPIK3R1ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL21621172 | 0.75 | NQO2 (0.38) | PIK3CAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL28457879 | 0.75 | PIK3CA (0.41) | PIK3CAPIK3R1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| EP-4169918-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3K FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4169917-B1 | QUINAZOLINE COMPOUNDS AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-3560921-B1 | QUINAZOLINE COMPOUND, PREPARATION METHOD, APPLICATION AS PI3K INHIBITOR FOR THE TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSTION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2024-08-14 | — | — | EP | disclosed |
| EP-4169918-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169917-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| US-11534443-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11534443-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-27 | — | — | US | disclosed |
| CN-108239076-B | Quinazoline compound, preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2021-07-06 | — | — | CN | disclosed |
| US-20210128559-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210128559-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-3560921-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018121550-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | 中国医学科学院药物研究所 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3R5, JAK1 | PIK3CA 1/4885PIK3R1 18/4885ALDH1A1 3118/4885 |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3R1 39/4885ALDH1A1 4244/4885 |
| US-11534443-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3R1 39/4885ALDH1A1 4244/4885 |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3C2A, PIK3R5 | PIK3CA 1/4885PIK3R1 34/4885ALDH1A1 3168/4885 |
| US-20210128559-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3R1 39/4885ALDH1A1 4244/4885 |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3R1 39/4885ALDH1A1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.